M. Simiele

发表

Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.

G. di Perri, A. Calcagno, A. D’Avolio, 2011, AIDS.

Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations

Marco Siccardi, Stefano Bonora, G. di Perri, 2011, Antimicrobial Agents and Chemotherapy.

Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients

G. di Perri, A. Calcagno, F. Castelli, 2017, Journal of Antimicrobial Chemotherapy.

Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia

G. Saglio, G. di Perri, A. Calcagno, 2014, Therapeutic drug monitoring.

UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells.

M. Rizzetto, G. di Perri, A. de Nicolò, 2014, Journal of pharmaceutical and biomedical analysis.

Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients.

G. di Perri, A. de Nicolò, A. D’Avolio, 2014, Journal of pharmaceutical and biomedical analysis.

TITLE: Intracellular antiviral activity of low-dose ritonavir in

A. Calcagno, A. D’Avolio, S. Bonora, 2014 .

A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir.

G. di Perri, A. de Nicolò, A. D’Avolio, 2013, Journal of pharmaceutical and biomedical analysis.

A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

G. di Perri, A. D’Avolio, M. Siccardi, 2011, Journal of pharmaceutical and biomedical analysis.

Class-specific relative genetic contribution for key antiretroviral drugs.

G. di Perri, A. Calcagno, A. Owen, 2015, The Journal of antimicrobial chemotherapy.

A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma.

F. Favata, G. di Perri, A. de Nicolò, 2016, Journal of pharmaceutical and biomedical analysis.

New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.

G. Saglio, G. di Perri, F. Di Carlo, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment

M. Rizzetto, G. di Perri, A. Calcagno, 2012, Therapeutic drug monitoring.

Pharmacokinetics of Switching Unboosted Atazanavir Coadministered with Tenofovir Disoproxil Fumarate from 400 Mg Once Daily to 200 Mg Twice Daily in HIV-Positive Patients

A. Calcagno, A. D’Avolio, M. Siccardi, 2011, Antiviral therapy.

Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance

V. Soriano, H. McLeod, S. Khoo, 2010, Antimicrobial Agents and Chemotherapy.

Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots.

V. Ranieri, F. D. De Rosa, G. di Perri, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.

G. di Perri, M. Boffito, D. Back, 2014, The Journal of antimicrobial chemotherapy.

Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes

P. Brusa, A. D’Avolio, M. Collino, 2019, Front. Pharmacol..

Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism

A. Lazzarin, G. di Perri, A. Calcagno, 2010, Pharmacogenetics and genomics.

How effective is [corrected] the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring?

A. D’Avolio, M. Simiele, L. Baietto, 2014, Bioanalysis.

Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.

A. Lazzarin, G. di Perri, A. Calcagno, 2013, Journal of Antimicrobial Chemotherapy.

Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.

G. di Perri, A. Calcagno, A. D’Avolio, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients

G. di Perri, R. Pellicano, G. Saracco, 2019, Medicina.

A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma.

G. di Perri, A. D’Avolio, S. Bonora, 2014, Journal of pharmaceutical and biomedical analysis.

A Validated High-Performance Liquid Chromatography-Ultraviolet Method for Quantification of the CCR5 Inhibitor Maraviroc in Plasma of HIV-Infected Patients

G. di Perri, A. D’Avolio, M. Siccardi, 2010, Therapeutic drug monitoring.

Sequential therapy with entecavir and PEG‐INF in patients affected by chronic hepatitis B and high levels of HBV‐DNA with non‐D genotypes

G. di Perri, A. D’Avolio, V. Ghisetti, 2013, Journal of viral hepatitis.

Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS.

F. D. De Rosa, G. di Perri, A. D’Avolio, 2012, The Journal of antimicrobial chemotherapy.

Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma

F. D. De Rosa, G. di Perri, A. D’Avolio, 2010, Antimicrobial Agents and Chemotherapy.

Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification.

V. Ranieri, G. di Perri, Debora Pensi, 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).

G. Saglio, G. di Perri, F. Di Carlo, 2012, Journal of pharmaceutical and biomedical analysis.

A LC-MS method to quantify tenofovir urinary concentrations in treated patients.

Stefano Bonora, Andrea Calcagno, G. di Perri, 2015, Journal of pharmaceutical and biomedical analysis.

UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.

G. di Perri, Debora Pensi, A. de Nicolò, 2015, Journal of pharmaceutical and biomedical analysis.

UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma

F. Favata, G. di Perri, A. de Nicolò, 2017, Journal of pharmaceutical and biomedical analysis.

Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.

G. di Perri, A. Calcagno, A. D’Avolio, 2014, The Journal of antimicrobial chemotherapy.

Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function

G. di Perri, A. Calcagno, I. Motta, 2013, Antimicrobial Agents and Chemotherapy.

An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients

A. D’Avolio, M. Siccardi, S. Bonora, 2008, Therapeutic drug monitoring.

Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients.

G. di Perri, A. Calcagno, A. de Nicolò, 2012, Journal of pharmaceutical and biomedical analysis.

Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms.

F. Patti, G. di Perri, A. Calcagno, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment

G. di Perri, A. Calcagno, G. Mengozzi, 2016, AIDS.

Intracellular Antiviral Activity of Low-Dose Ritonavir in Boosted Protease Inhibitor Regimens

G. di Perri, A. Calcagno, A. de Nicolò, 2014, Antimicrobial Agents and Chemotherapy.

Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment

M. Rizzetto, G. di Perri, A. Calcagno, 2012, Therapeutic drug monitoring.

Cannabinoids concentration variability in cannabis olive oil galenic preparations

G. di Perri, A. de Nicolò, A. D’Avolio, 2018, The Journal of pharmacy and pharmacology.

Steady State Pharmacokinetic of Ritonavir-boosted Atazanavir in 31 Pregnant Women before and after Delivery.

D. Cattaneo, F. Maggiolo, D. Ripamonti, 2010 .

Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma

A. D’Avolio, M. Siccardi, S. Garazzino, 2010, Analytical and bioanalytical chemistry.

Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors.

G. di Perri, A. Calcagno, A. D’Avolio, 2013, The Journal of antimicrobial chemotherapy.

Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.

G. di Perri, A. Calcagno, A. D’Avolio, 2012, British journal of clinical pharmacology.

Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting

A. Calcagno, A. Owen, D. Back, 2012, Therapeutic drug monitoring.

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.

G. di Perri, A. Calcagno, I. Motta, 2014, The Journal of antimicrobial chemotherapy.

Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.

F. D. De Rosa, G. di Perri, A. Calcagno, 2014, Pharmacogenomics.

Efavirenz pharmacogenetics in a cohort of Italian patients.

G. di Perri, A. Calcagno, A. D’Avolio, 2016, International journal of antimicrobial agents.

Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV).

A. Calcagno, A. D’Avolio, M. Siccardi, 2010 .

HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions.

G. di Perri, A. D’Avolio, M. Siccardi, 2010, Journal of pharmaceutical and biomedical analysis.

Cannabis-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability

P. Brusa, A. D’Avolio, M. Collino, 2021, Pharmaceuticals.

Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single‐nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4

M. Rizzetto, G. di Perri, A. Calcagno, 2011, Hepatology.

2002 SLC28A2 65C>T PREDICT SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS C TREATED WITH INTERFERON AND RIBAVIRIN, CONSIDERING ALL HCV GENOTYPE AND GENOTYPE 1/4

M. Rizzetto, A. Calcagno, A. D’Avolio, 2010 .

F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy

M. Rizzetto, A. D’Avolio, M. Simiele, 2012 .

Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.

A. Lazzarin, G. di Perri, A. Calcagno, 2014, The Journal of antimicrobial chemotherapy.

Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi.

G. di Perri, A. Calcagno, I. Motta, 2015, British journal of clinical pharmacology.

Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population.

G. di Perri, M. Siccardi, F. Carraro, 2012, Therapeutic drug monitoring.

Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole.

F. Patti, G. di Perri, A. Calcagno, 2015, Therapeutic drug monitoring.

Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines

M. Mussa, A. Calcagno, A. D’Avolio, 2015, The Pharmacogenomics Journal.

Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma

F. D. De Rosa, G. di Perri, Debora Pensi, 2013, Therapeutic drug monitoring.

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics

G. di Perri, A. Calcagno, A. D’Avolio, 2012, AIDS.

Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots.

F. D. De Rosa, G. di Perri, A. D’Avolio, 2014, Journal of pharmaceutical and biomedical analysis.

Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells.

G. di Perri, A. Calcagno, A. D’Avolio, 2013, The Journal of antimicrobial chemotherapy.

High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis

A. Calcagno, A. D’Avolio, M. Tettoni, 2013 .

Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients.

G. di Perri, A. Calcagno, I. Motta, 2016, AIDS research and human retroviruses.